中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2012年
10期
840-843
,共4页
刘顺%谭茗月%赵水平%荣惠
劉順%譚茗月%趙水平%榮惠
류순%담명월%조수평%영혜
高脂血症%血红素氧化酶(脱环)%多廿烷醇
高脂血癥%血紅素氧化酶(脫環)%多廿烷醇
고지혈증%혈홍소양화매(탈배)%다입완순
Hyperlipidemia%Heme oxygenase(decyclizing)%Policosanol
目的 评价多廿烷醇治疗高脂血症的疗效和安全性,并观察其对血红素氧合酶1(HO-1)的作用.方法 72例高脂血症患者随机分为两组:治疗组(n=36):多廿烷醇20 mg/d；安慰剂组(n=36):安慰剂2片/d.两组均随访治疗16周,观察两组治疗前后血脂谱及血清高敏C反应蛋白(hs-CRP)、HO-1水平的变化,同时监测药物不良反应.HO-1采用ELISA法进行检测.结果 (1)经过16周治疗后,治疗组总胆固醇(TC)由(7.01±1.03) mmol/L下降至(5.66±0.83) mmol/L(P＜0.01),均数降低19.4％；低密度脂蛋白胆固醇(LDL-C)由(4.78±0.72) mmol/L下降至(3.70±0.69) mmol/L(P ＜0.01),均数降低22.5％；甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)无显著变化；HO-1由(1.82±1.08) μg/L下降至(1.45±0.81) μg/L(P ＜0.01)；hs-CRP由(3.40±3.64) mg/L下降至(1.86 ±2.02)mg/L(P＜0.01).(2)两组的各项安全性指标在治疗前后均无显著变化(P＞0.05),随访过程中无过敏反应、肌肉痛等不良反应发生.结论 多廿烷醇(20 mg/d)可显著降低血清胆固醇,并降低HO-1、hs-CRP水平,提示其有抗氧化应激的作用.多廿烷醇治疗高脂血症不良反应少,具有较好的安全性.
目的 評價多廿烷醇治療高脂血癥的療效和安全性,併觀察其對血紅素氧閤酶1(HO-1)的作用.方法 72例高脂血癥患者隨機分為兩組:治療組(n=36):多廿烷醇20 mg/d；安慰劑組(n=36):安慰劑2片/d.兩組均隨訪治療16週,觀察兩組治療前後血脂譜及血清高敏C反應蛋白(hs-CRP)、HO-1水平的變化,同時鑑測藥物不良反應.HO-1採用ELISA法進行檢測.結果 (1)經過16週治療後,治療組總膽固醇(TC)由(7.01±1.03) mmol/L下降至(5.66±0.83) mmol/L(P＜0.01),均數降低19.4％；低密度脂蛋白膽固醇(LDL-C)由(4.78±0.72) mmol/L下降至(3.70±0.69) mmol/L(P ＜0.01),均數降低22.5％；甘油三酯(TG)、高密度脂蛋白膽固醇(HDL-C)無顯著變化；HO-1由(1.82±1.08) μg/L下降至(1.45±0.81) μg/L(P ＜0.01)；hs-CRP由(3.40±3.64) mg/L下降至(1.86 ±2.02)mg/L(P＜0.01).(2)兩組的各項安全性指標在治療前後均無顯著變化(P＞0.05),隨訪過程中無過敏反應、肌肉痛等不良反應髮生.結論 多廿烷醇(20 mg/d)可顯著降低血清膽固醇,併降低HO-1、hs-CRP水平,提示其有抗氧化應激的作用.多廿烷醇治療高脂血癥不良反應少,具有較好的安全性.
목적 평개다입완순치료고지혈증적료효화안전성,병관찰기대혈홍소양합매1(HO-1)적작용.방법 72례고지혈증환자수궤분위량조:치료조(n=36):다입완순20 mg/d；안위제조(n=36):안위제2편/d.량조균수방치료16주,관찰량조치료전후혈지보급혈청고민C반응단백(hs-CRP)、HO-1수평적변화,동시감측약물불량반응.HO-1채용ELISA법진행검측.결과 (1)경과16주치료후,치료조총담고순(TC)유(7.01±1.03) mmol/L하강지(5.66±0.83) mmol/L(P＜0.01),균수강저19.4％；저밀도지단백담고순(LDL-C)유(4.78±0.72) mmol/L하강지(3.70±0.69) mmol/L(P ＜0.01),균수강저22.5％；감유삼지(TG)、고밀도지단백담고순(HDL-C)무현저변화；HO-1유(1.82±1.08) μg/L하강지(1.45±0.81) μg/L(P ＜0.01)；hs-CRP유(3.40±3.64) mg/L하강지(1.86 ±2.02)mg/L(P＜0.01).(2)량조적각항안전성지표재치료전후균무현저변화(P＞0.05),수방과정중무과민반응、기육통등불량반응발생.결론 다입완순(20 mg/d)가현저강저혈청담고순,병강저HO-1、hs-CRP수평,제시기유항양화응격적작용.다입완순치료고지혈증불량반응소,구유교호적안전성.
Objective To evaluate the effects of policosanol on serum lipid and heme oxygenase-1 (HO-1) in patients with byperlipidemia.Methods This randomized,open study included 72 patients with hyperlipidemia.The patients were randomly assigned to treatment group (policosanol,20 mg/d,n =36) or placebo group (placebo,two tablets/d,n =36).The levels of serum lipids,hypersensitive C-reactive protein (hs-CRP),HO-1 were assessed before and after 16 weeks treatment.Drug-induced adverse effects and events were recorded during the observation period.The serum HO-1 was measured by ELISA.Results (1) After 16 weeks,all parameters remained unchanged in the placebo group; the level of TC decreased from (7.01 ± 1.03)mmol/L to (5.66 ±0.83)mmol/L(-19.4％,P ＜0.01),the level of LDL-C decreased from (4.78 ± 0.72) mmol/L to (3.70 ± 0.69) mmol/L(-22.5％,P ＜ 0.01) in the treatment group.TG and HDL-C levels remained unchanged (P ＞ 0.05) while the level of HO-1 significantly decreased from (1.82 ± 1.08) μg/L to (1.45 ±0.81) μg/L (P ＜0.01) and the level of hs-CRP decreased from (3.40 ± 3.64) mg/L to (1.86 ± 2.02) mg/L (P ＜ 0.01) in the treatment group.(2) Safety index was similar between placebo and treatment groups (P ＞ 0.05) and there was no adverse events including allergic reaction,muscle pain in all subjects during the observation period.Conclusion The short-term data obtained from this small hyperlipidemia patient cohort suggest that policosanol is a safe lipid-lowering and anti-inflammatory agent for hyperlipidemia patients.
